-+ 0.00%
-+ 0.00%
-+ 0.00%

Lifeward outlines rehabilitation robotics growth strategy, highlights reimbursement coverage moat

PUBT·09/08/2026 13:00:07
Listen to the news
Lifeward outlines rehabilitation robotics growth strategy, highlights reimbursement coverage moat
  • Lifeward outlined a strategy to scale its rehabilitation robotics platform, citing reimbursement coverage as a key competitive moat.
  • ReWalk reimbursement framework highlighted: HCPCS K1007, about 46% Medicare Advantage access, Medicare Fee Schedule rate USD 95,081.
  • Operating snapshot as of June 30, 2026: LTM revenue USD 21.8 million, cash USD 11 million, Q2 revenue USD 6.6 million.
  • Pipeline timing targets: AlterG StrideSense in 2027, upper-body exoskeleton in 2028, ReWalk X in early 2029.
  • Oramed partnership described as funding support of up to USD 47 million, including a 4% ReWalk royalty over 10 years.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.